SCHEMBL798102

SCHEMBL798102

CC(=O)/C=C/c1ccc(C(C)(C)C)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.75
TDP1 Q9NUW8 2/20 0.59
GLA P06280 1/20 0.59
SMN1; SMN2 Q16637 6/20 0.57
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
MAPT P10636 4/20 0.57
TRPV1 Q8NER1 3/20 0.57
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 3/20 0.54
HPGD P15428 3/20 0.54
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.53
IAPP P10997 1/20 0.52
PTGS1 P23219 1/20 0.52
TP53 P04637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11395099 1.00 CYP1A2 (0.75) CYP1A2TDP1GLASMN1; SMN2NPC1
SCHEMBL26382466 0.86 CYP1A2 (1.00) CYP1A2SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1359335 0.85 GLA (0.77) CYP1A2TDP1GLAMAPTALDH1A1
SCHEMBL1359336 0.85 GLA (0.77) CYP1A2TDP1GLAMAPTALDH1A1
SCHEMBL846833 0.84 CYP1A2 (0.75) CYP1A2TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL818742 0.84 CYP1A2 (0.75) CYP1A2TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL4001354 0.84 CYP1A2 (0.75) CYP1A2TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL12993089 0.82 CYP1A2 (0.72) CYP1A2TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL1405020 0.82 CYP1A2 (0.72) CYP1A2TDP1GLAHDAC1
SCHEMBL2224514 0.82 CYP1A2 (0.72) CYP1A2TDP1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20100197657-A1 2-ARYL OR HETEROARYL INDOLE DERIVATIVES CHANG RONALD K 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197657-A1 2-ARYL OR HETEROARYL INDOLE DERIVATIVES ASIC1, ASIC3, TRPV1 CYP1A2 1795/4885TDP1 3953/4885GLA 4000/4885
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 CYP1A2 1837/4885TDP1 1799/4885GLA 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.